Osage Partners, of Bala Cynwyd, has raised $100 million for a venture capital fund that has teamed up with eight universities and is focused on investing in start-ups that emerge from work being done on campus.
Called Osage University Partners I, the fund will invest in both early- and late-stage companies involved in a wide range of industries, such as therapeutics, medical diagnostics, advanced materials, cleantech and software.
Managing partner Marc Singer said the fund enables the universities to participate in venture-capital rounds they'd previously were unable to fund. Osage has signed contracts with the University of Pennsylvania and seven other institutions:
- California Institute of Technology;
- Columbia University;
- Duke University;
- University of California at Berkeley;
- University of Florida;
- University of Michigan;
- Yale University.
The rising tide that was the U.S. stock market in 2010 lifted many of the dinghies, trawlers and supertankers of the Philadelphia corporate world.
But it’s easy to see the dents and leaks left by the financial crisis and recession. The ranks of the good ship Inquirer/Bloomberg Philadelphia Index have been thinned significantly over the last three years.
Delistings, acquisitions, and the relocation of corporate headquarters have all played a part in winnowing the index to 181 members.
Sorry, savers of a certain age, but the rates on some of your savings bonds just went down again.
For the Series I Savings Bond, the rate will be 0.74 percent on bonds bought between Monday and April 30, 2011, the federal Bureau of the Public Debt announced Monday.
That includes a fixed rate of 0 percent, which applies for the 30-year interest-bearing life of the bond, and an inflation-adjusted rate of 0.74 percent. That variable rate changes every May 1 and Nov. 1.
Without its vibrant biotechnology sector, Philadelphia would barely rate as a region that venture capitalists might want to visit once in awhile.
That’s clear from the quarterly MoneyTree Report, released Friday by PricewaterhouseCoopers and National Venture Capital Association.
The report, which uses data from Thomson Reuters, shows 10 of the 31 venture financings of Philadelphia-area companies during the third quarter were for biotechnology firms.
As I look back on the stock market in the first half of 2010, it’s hard to see any fireworks among local publicly held companies.
I reviewed changes in the Inquirer/Bloomberg Philadelphia Index, which is composed of the stocks of 189 area companies. The index was down 6.83 percent during the six months ended June 30, compared with the 7.57 percent decline in the Standard & Poor’s 500 Index.
Considering only companies whose stock prices traded above $3 as of Dec. 31, I came up with the following list of ooohs and aaaws:
How appropriate to celebrate the two-week anniversary of the “flash crash” with another steep sell-off.
On Thursday, there was no 1,000-point drop in minutes to unnerve professional investors and novices alike. Rather, it was like watching a bout between mismatched boxers. The decision was never in doubt, only the extent of the damage.
The Dow closed down 376.36 points, which was 28.56 points worse than how flash-crash day finished.
More than five weeks after Tengion Inc. netted $26 million from its initial public offering, another local life-sciences company hopes to travel the same path.
NuPathe Inc. of Conshohocken filed a registration statement with the Securities and Exchange Commission on Friday seeking to raise $86.3 million.
The specialty pharmaceutical company, which had 21 employees as of April 30, has been working on Zelrix, a single-use skin patch to treat migraines.
NuPathe Inc., of Conshohocken, hopes to raise $86.3 million in an initial public offering, according to a regulatory filing on Friday.
The preliminary prospectus does not list the number of shares NuPathe intends to issue or any price range.
The specialty pharmaceutical company has been working on Zelrix, a single-use patch to treat migraine. In a filing with the Securities and Exchange Commission, NuPathe said it completed a Phase III clinical trial in July 2009 and expects to submit a new drug application with the Food and Drug Administration in the fourth quarter of this year.